XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1

5) Stock-based Compensation: Schedule of stock inventive plan changes (Tables)

3 Months Ended

Mar. 31, 2018

Tables/Schedules

Schedule of stock inventive plan changes

		Number of Class A Shares		Weighted Average Exercise Price		Number of Class C Shares		Weighted Average Exercise Price
Outstanding at December 31, 2017		880,426		$      4.35		523,603		$      5.24
Granted		-				-
Exercised		(31,984)				-
Cancelled		(5,704)				-
Outstanding at March 31, 2018		842,738		$      4.48		523,603		$      5.24
As of March 31, 2018:
Options exercisable		744,686		$      4.40		468,477		$      5.29
As of March 31, 2018:
Available options for future grant		421,241				165,638
Weighted average contractual term of options
outstanding at March 31, 2018		6.55 years				3.19 years
Weighted average contractual term of options
exercisable at March 31, 2018		6.53 years				2.43 years
Aggregated intrinsic value of options
outstanding at March 31, 2018 (1)		$850,528				$251,961
Aggregated intrinsic value of options
exercisable at March 31, 2018 (1)		$836,882				$232,667
(1) The Company used a stock price of $5.15 as of March 31, 2018 to derive intrinsic value.

A summary of the status of the Company’s stock compensation plans as of March 31, 2017, and the changes during the three months ended March 31, 2017, are presented below:

		Number of Class A Shares		Weighted Average Exercise Price		Number of Class C Shares		Weighted Average Exercise Price
Outstanding at December 31, 2016		741,973		$      4.33		556,298		$      4.61
Granted		-				-
Exercised		-				-
Cancelled		-				-
Outstanding at March 31, 2017		741,973		$      4.33		556,298		$      4.61
As of March 31, 2017:
Options exercisable		636,764		$      3.94		493,298		$      4.26
As of March 31, 2017:
Available options for future grant		253,432				-
Weighted average contractual term of options
outstanding at March 31, 2017		7.12 years				2.42 years
Weighted average contractual term of options
exercisable at March 31, 2017		6.70 years				2.13 years
Aggregated intrinsic value of options
outstanding at March 31, 2017 (1)		$1,837,828				$1,264,540
Aggregated intrinsic value of options
exercisable at March 31, 2017 (1)		$1,824,086				$1,264,540
(1) The Company used a stock price of $6.80 as of March 31, 2017 to derive intrinsic value.

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlockSupplementAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration